Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 9/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28023330 | 0.88 | NPC1 (0.54) | ABCB1NPC1RAB9AGPR52KCNH2 | |
| SCHEMBL15979734 | 0.86 | CTNNB1 (0.71) | NPC1RAB9AKMT2ACTNNB1WNT3A | |
| SCHEMBL8558334 | 0.84 | RAB9A (0.69) | ABCB1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3739850 | 0.84 | PPARA (0.60) | ABCB1NPC1MEN1KMT2ATP53 | |
| SCHEMBL2336465 | 0.83 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2AHPGD | |
| SCHEMBL3282912 | 0.83 | NPC1 (0.63) | NPC1RAB9AGPR52MEN1KMT2A | |
| SCHEMBL5081630 | 0.83 | CTNNB1 (0.63) | NPC1KMT2ACTNNB1WNT3AHDAC8 | |
| SCHEMBL30609633 | 0.83 | CTNNB1 (0.63) | NPC1KMT2ACTNNB1WNT3AHDAC8 | |
| SCHEMBL29861033 | 0.83 | NPC1 (0.63) | NPC1RAB9AGPR52MEN1KMT2A | |
| SCHEMBL28249508 | 0.82 | ABCB1 (0.64) | ABCB1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| US-6653508-B2 | Use treating various medical conditions, including pain | GRUENENTHAL GMBH (DE) | 2003-11-25 | — | — | US | disclosed |
| US-20020161262-A1 | 3-Amino-2-benzyl-1-phenylpropane derivatives | GRUENTENTHAL GMBH (DE) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161262-A1 | 3-Amino-2-benzyl-1-phenylpropane derivatives | PYGL, CYP11B2, GOT2 | ABCB1 63/4885NPC1 11/4885RAB9A 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.